Togawa A
Division of Internal Medicine, International Medical Center of Japan.
Nihon Rinsho. 1995 Mar;53(3):642-6.
The introduction of melphalan therapy produced improvement in either response rates or survival of patients with myeloma. Since then, many attempts have been carried out to improve the results achievable with MP therapy by the use of combination chemotherapy, but no difference in survival was found. Recent efforts have evaluated dose intensification for patients with good risk factor to from the viewpoint of bone marrow ablation requiring hematopoietic stem cell support, though these approaches may be ineffective for patients with refractory myeloma.
美法仑疗法的引入使骨髓瘤患者的缓解率或生存率得到了改善。从那时起，人们进行了许多尝试，通过联合化疗来提高MP疗法的疗效，但未发现生存率有差异。最近的研究从需要造血干细胞支持的骨髓消融角度评估了对具有良好危险因素的患者进行剂量强化治疗，尽管这些方法对难治性骨髓瘤患者可能无效。
